Anderson B D, Chiang C Y
Department of Pharmaceutics, College of Pharmacy, University of Utah, Salt Lake City 84112.
J Pharm Sci. 1990 Sep;79(9):787-90. doi: 10.1002/jps.2600790908.
(+-)-Carbovir [(+-)-9-[4 alpha-(hydroxymethyl)-cyclopent-2-ene-1 alpha-yl]guanine; NSC 614846] is a novel carbocyclic nucleoside analogue which has been shown to be a potent and selective inhibitor of HIV in vitro. As part of an effort to develop a parenteral formulation for subsequent clinical and toxicological evaluation of this compound, the aqueous solution stability of carbovir as a function of pH and temperature and various physicochemical properties of carbovir including its pKa, solubility versus pH and solvent composition, and octanol-water partition coefficient have been examined. Ultraviolet spectrophotometry indicated that carbovir has pKa values of 3.15 and 9.68, respectively, at 25 degrees C and 0.01 ionic strength. The aqueous solubility of carbovir over the pH range 7-10.5 was consistent with that expected of a weak acid with a pKa of 9.65 and an intrinsic solubility of 1.24 mg/mL. Due to the limited solubility of carbovir at physiological pH, methods for solubilizing carbovir in aqueous solution were explored, including propylene glycol-water cosolvents and complexation with hydroxypropyl-beta-cyclodextrin. As expected for carbovir, a semipolar compound with an octanol-water partition coefficient of 0.29, propylene glycol:water cosolvents were not highly effective in enhancing solubility. Complex formation between carbovir and 2-hydroxypropyl-beta-cyclodextrin was found to be more effective, with a K1:1 of 105 M-1 for the complexation. The pH profiles generated at 50, 70, and 90 degrees C were accounted for by acid-catalyzed degradation at low pH leading to the formation of guanine and a neutral degradation pathway which dominates above pH 4. Prototype lyophilized formulations containing (after reconstitution) 10 mg/mL of carbovir at a pH of 10.6 were developed and evaluated.
(±)-卡波韦[(±)-9-[4α-(羟甲基)-环戊-2-烯-1α-基]鸟嘌呤;NSC 614846]是一种新型碳环核苷类似物,已被证明在体外是一种有效的HIV选择性抑制剂。作为开发用于该化合物后续临床和毒理学评估的肠胃外制剂工作的一部分,研究了卡波韦水溶液稳定性与pH和温度的关系,以及卡波韦的各种物理化学性质,包括其pKa、溶解度与pH和溶剂组成的关系,以及正辛醇-水分配系数。紫外分光光度法表明,在25℃和0.01离子强度下,卡波韦的pKa值分别为3.15和9.68。卡波韦在pH值7-10.5范围内的水溶性与pKa为9.65、固有溶解度为1.24mg/mL的弱酸预期情况一致。由于卡波韦在生理pH下溶解度有限,探索了在水溶液中增溶卡波韦的方法,包括丙二醇-水混合溶剂以及与羟丙基-β-环糊精络合。正如卡波韦这种正辛醇-水分配系数为0.29的半极性化合物所预期的那样,丙二醇:水混合溶剂在提高溶解度方面效果不佳。发现卡波韦与2-羟丙基-β-环糊精之间形成络合物更有效,络合的K1:1为105 M-1。在50、70和90℃下生成的pH曲线是由低pH下的酸催化降解导致鸟嘌呤形成以及pH高于4时占主导的中性降解途径所解释的。开发并评估了冻干原型制剂(复溶后),其含有pH为10.6的10mg/mL卡波韦。